Cancer Drug Parity Act of 2026 ensures cost-sharing for oral anticancer drugs is no less favorable than for injectable drugs.
The Cancer Drug Parity Act of 2026 amends the Employee Retirement Income Security Act of 1974 to mandate that group health plans provide cost-sharing for oral anticancer drugs on terms no less favorable than for injectable drugs. It prohibits plans from imposing higher out-of-pocket costs for oral drugs or applying more restrictive limitations. The Act also requires the Comptroller General to study the impact of these changes and report to Congress. The changes take effect for plan years beginning on or after January 1, 2027.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.